Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Exclusive antagonism of the a4 ß7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates.

Exclusive antagonism of the a4 ß7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis. 2012 Nov; 18(11):2107-19.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.